BIO Calls for 14-Year Data-Exclusivity Period for Biologics

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Washington, DC (May 3)-The Biotechnology Industry Organization published a position paper stating that any legislation establishing a regulatory pathway for follow-on biologics should grant pioneering products 14 years of data exclusivity.

Washington, DC (May 3)-The Biotechnology Industry Organization (BIO, www.bio.org) published a position paper stating that any legislation establishing a regulatory pathway for follow-on biologics should grant pioneering products 14 years of data exclusivity. The organization defines data exclusivity as the time period after the innovator’s product is approved during which the US Food and Drug Administration (Rockville, MD, www.fda.gov) may not approve a follow-on biologic (FOB) product that relies on the innovator product’s safety and effectiveness.

“For biologics to receive the same length of effective market protection that small- molecule drugs receive under the Hatch-Waxman Act, the period of data exclusivity in any FOBs framework must be no less than 14 years,” said Jim Greenwood, BIO’s president and CEO in a prepared statement. “Anything less could skew investment away from biologics research and development, jeopardizing the development of future pioneering biomedical advances.”   

BIO asserts that a FOBs regime would create a “patent protection gap” that would allow a follow-on manufacturer to elude an innovator’s patents while still relying on the innovator’s product to bypass the full regulatory process because of two factors not present in the Hatch-Waxman construct for small-molecule drugs. First, unlike a generic drug, which must be the same as an innovator product, a follow-on biologic may be only “similar” to the corresponding innovator product. Second, because biologic products are large molecules produced by living cells, patent protection for such products is often narrower and easier to “design around,” than that of small-molecules drugs.

Greenwood remarked that a 14-year exclusivity period for biologics would be consistent with previous Congressional efforts to protect the pharmaceutical industry. “Given that Congress has previously concluded that up to 14 years of patent protection is appropriate for drugs and biologic products, any statutory formula that allows for follow-on biologics should allow for at least the same degree of effective market protection,” Greenwood said in a prepared statement.

Data exclusivity is particularly important for the biotechnology industry, BIO observes, because the industry is composed mainly of small companies with unstable funding. The organization notes that these companies would be vulnerable to follow-on biologics legislation that could change the investment incentives.

Click here for the full text of BIO’s data-exclusivity justification paper.

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes